Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed Wegovy for weight loss in a ... more body weight reduction due to tirzepatide. By comparison, those who received semaglutide experienced ...

Women typically lose more weight on Zepbound and Wegovy than men do ... want to consider detailed results on how the two medicines compare across different types of patients before making ...

Women typically lose more weight on Zepbound and Wegovy than men do. Doctors will probably want to consider detailed results on how the two medicines compare across different types of patients ...

according to detailed results from a direct comparison trial published in The New England Journal of Medicine. On average, those taking Zepbound lost 50.3 pounds, while those on Wegovy lost 33.1 ...

though 6.1% of those in the Zepbound arm discontinued treatment due to adverse events. By comparison, 8.0% of participants the Wegovy arm discontinued treatment. Lilly added that the study was not ...